Division of Oral and Maxillofacial Surgery, Meikai University School of Dentistry, Sakado, Saitama 350-0283, Japan.
Anticancer Res. 2012 Nov;32(11):4823-32.
Despite frequent use of topoisomerase inhibitors (TIs) as antitumor agents, their application to oral squamous cell carcinoma (OSCC) has not been reported. We investigated three inhibitors of topoisomerase I [camptothecin, irinotecan, SN-38 (active metabolite of irinotecan)] and two inhibitors of topoisomerase II (etoposide, teniposide) for their cytotoxicity towards a total of 15 human tumor cell lines and normal cultured cells. All TIs exhibited higher cytotoxicity towards tumor cell lines (OSCC, glioblastoma, myelogenous leukemia) as compared with normal mesenchymal (gingival fibroblast, pulp cell, periodontal ligament fibroblast) and epithelial cells (skin keratinocytes). Among TIs, SN-38 had the highest cytotoxicity towards OSCC cell lines, with a tumor specificity index of 1321 compared to mesenchymal cells and 22 compared with epithelial cells. SN-38 induced different types of cell death in two OSCC cell lines: apoptosis (caspase-3 activation and internucleosomal DNA fragmentation) in HSC-2 cells and autophagy (formation of autophagosome and secondary lysosome) in HSC-4 cells. The cell death of HSC-2 and HSC-4 cells was significantly inhibited by pre-treatment with caspase inhibitor (Z-VAD-FMK) and autophagy inhibitors (3-methyladenine, bafilomycin A1), respectively. The present study demonstrated that SN-38 is highly cytotoxic to OSCC cell lines, regardless of the type of induced cell death, suggesting its future application for chemotherapy of OSCC.
尽管拓扑异构酶抑制剂 (TIs) 经常被用作抗肿瘤药物,但它们在口腔鳞状细胞癌 (OSCC) 中的应用尚未见报道。我们研究了拓扑异构酶 I 的三种抑制剂 [喜树碱、伊立替康、SN-38(伊立替康的活性代谢物)] 和拓扑异构酶 II 的两种抑制剂 [依托泊苷、替尼泊苷] 对总共 15 个人类肿瘤细胞系和正常培养细胞的细胞毒性。与正常间充质(牙龈成纤维细胞、牙髓细胞、牙周膜成纤维细胞)和上皮细胞(皮肤角质形成细胞)相比,所有 TIs 对肿瘤细胞系(OSCC、胶质母细胞瘤、髓性白血病)表现出更高的细胞毒性。在 TIs 中,SN-38 对 OSCC 细胞系的细胞毒性最高,与间充质细胞相比肿瘤特异性指数为 1321,与上皮细胞相比为 22。SN-38 在两种 OSCC 细胞系中诱导不同类型的细胞死亡:HSC-2 细胞中的凋亡(半胱天冬酶-3 激活和核小体间 DNA 片段化)和 HSC-4 细胞中的自噬(自噬体和次级溶酶体的形成)。用半胱天冬酶抑制剂 (Z-VAD-FMK) 和自噬抑制剂 (3-甲基腺嘌呤、巴弗洛霉素 A1) 预处理分别显著抑制了 HSC-2 和 HSC-4 细胞的细胞死亡。本研究表明,SN-38 对 OSCC 细胞系具有高度的细胞毒性,无论诱导的细胞死亡类型如何,这表明它在未来可能应用于 OSCC 的化疗。